A meta-analysis including 3,640 patients with heart failure and CKD from three randomized controlled trials (HARP-III, PARADIGM-HF, and PARAMOUNT) indicated that, compared with ACEI/ARB, ARNI significantly improved eGFR and decreased blood pressure and NT-proBNP levels (48). The gene discussed is NPPB; the disease is chronic kidney disease.